Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia
US7608616B1 · kind B1 · utility
4Cited by
1References
2Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 3, 2008 |
| Grant date | Oct 27, 2009 |
| Priority date | — |
| Expiry date | Jun 3, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/55
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein is a method for treating a patient with Quazepam that reduces the risk of an adverse interaction between the Quazepam and drug that is a substrate of the cytochrome P450 enzyme isoform 2B6 (CYP2B6 substrate drug), e.g., Bupropion. The method includes determining if the patient to be treated with Quazepam is being treated with a CYP2B6 substrate drug, and prescribing or treating the patient with Quazepam based on the determination.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.